4/11
08:06 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/11
06:08 am
fate
Rating for FATE
Medium
Report
Rating for FATE
4/11
06:08 am
fate
Rating for FATE
Medium
Report
Rating for FATE
3/19
08:08 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
2/27
10:57 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
10:57 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
10:10 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
10:10 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
09:36 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
09:36 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
08:47 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
08:47 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
08:08 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
2/27
07:38 am
fate
Rating for FATE
Medium
Report
Rating for FATE
2/27
07:38 am
fate
Rating for FATE
Medium
Report
Rating for FATE